| 1 |
Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials[J]. Lancet Respir Med, 2014, 2(8): 611-620.
|
| 2 |
Sinha P, Delucchi KL, McAuley DF, et al. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials[J]. Lancet Respir Med, 2020, 8(3): 247-257.
|
| 3 |
Dahmer MK, Yang G, Zhang M, et al. Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis[J]. Lancet Respir Med, 2022, 10(3): 289-297.
|
| 4 |
Sinha P, Kerchberger VE, Willmore A, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials[J]. Lancet Respir Med, 2023, 11(11): 965-974.
|
| 5 |
Sarma A, Christenson SA, Shoshana BZ, et al. Acute Respiratory Distress Syndrome Molecular Phenotypes Have Distinct Lower Respiratory Tract Transcriptomes[J]. Am J Respir Crit Care Med, 2025, 211(12): 2352-2362.
|
| 6 |
Lin M, Xu F, Deng Y, et al. Large-scale proteomic profiling identifies distinct inflammatory phenotypes in Acute Respiratory Distress Syndrome (ARDS): a multi-center, prospective cohort study[J]. Eur Respir J, 2026, 67(2): 2500933.
|
| 7 |
Alipanah-Lechner N, Neyton L, Sinha P, et al. Longitudinal multiomic signatures of ARDS and sepsis inflammatory phenotypes identify pathways associated with mortality[J]. J Clin Invest, 2025, 136(3): e196290.
|
| 8 |
Pensier J, Fosset M, Paschold BS, et al. Temporal stability of phenotypes of acute respiratory distress syndrome: clinical implications for early corticosteroid therapy and mortality[J]. Intensive Care Med, 2025, 51(10): 1784-1796.
|
| 9 |
Nasa P, Bos LD, Estenssoro E, et al. Defining and subphenotyping ARDS: insights from an international Delphi expert panel[J]. Lancet Respir Med, 2025, 13(7): 638-650.
|
| 10 |
Reddy K, Sinha P, Antcliffe DB, et al. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study[J]. Lancet Respir Med, 2026: S2213-2600(26)00040-8.
|
| 11 |
Delucchi K, Famous KR, Ware LB, et al. Stability of ARDS subphenotypes over time in two randomised controlled trials[J]. Thorax, 2018, 73(5): 439-445.
|
| 12 |
Renard Triché L, Fosset M, Jabaudon M, et al. Temporal stability of inflammatory subphenotypes of acute respiratory distress syndrome: 28-day insights from the ICAR trial[J]. Anaesth Crit Care Pain Med, 2025, 44(5): 101559.
|
| 13 |
van Amstel RBE, Bartek B, Vlaar APJ, et al. Temporal transitions of the hyperinflammatory and hypoinflammatory phenotypes in critical illness[J]. Am J Respir Crit Care Med, 2025, 211(3): 347-356.
|
| 14 |
Munroe ES, Spicer A, Castellvi-Font A, et al. Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill[J]. Lancet Respir Med, 2025, 13(6): 556-568.
|
| 15 |
Graham Linck EJ, Goligher EC, Semler MW, et al. Toward precision in critical care research: methods for observational and interventional studies[J]. Crit Care Med, 2024, 52(9): 1439-1450.
|
| 16 |
Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial[J]. Lancet Respir Med, 2020, 8(3): 267-276.
|
| 17 |
Smit JM, Van Der Zee PA, Stoof SCM, et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials[J]. Lancet Respir Med, 2025, 13: 221-233.
|
| 18 |
Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial[J]. JAMA, 2015, 313(7): 677-686.
|
| 19 |
Michels EHA, Dequin PF, Butler JM, et al. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial[J]. Lancet Respir Med, 2026, 14(4): 327-340.
|
| 20 |
Smit JM, Krijthe JH, Lloyd M, et al. From severity-guided to CRP-guided corticosteroid treatment[J]. Am J Respir Crit Care Med, 2026: aamag070.
|
| 21 |
Jones BE, Ramirez JA, Oren E, et al. Diagnosis and Management of Community-acquired Pneumonia: An Official American Thoracic Society Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2026, 212(1): 24-44.
|
| 22 |
Soumare A, Kapfer T, Botrel T, et al. Systemic Corticosteroids, Mortality, and Infections in Pneumonia and Acute Respiratory Distress Syndrome : A Systematic Review and Meta-analysis[J]. Ann Intern Med, 2026, 179(1): 67-80.
|
| 23 |
Reyes LF, Martin-Loeches I. Corticosteroids in community-acquired pneumonia: a step forward, but questions remain[J]. Lancet Respir Med, 2025, 13(3): 191-193.
|
| 24 |
Smit JM, Krijthe JH, Meduri GU, et al. C-reactive protein-guided treatment in pneumonia: charting a personalised approach - Authors' reply[J]. Lancet Respir Med, 2025, 13(5): e25-e26.
|
| 25 |
Meiser A, Volk T, Wallenborn J, et al; Sedaconda study group. Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial[J]. Lancet Respir Med, 2021, 9(11): 1231-1240.
|
| 26 |
Jabaudon M, Quenot JP, Badie J, et al. Inhaled sedation in acute respiratory distress syndrome: the SESAR randomized clinical trial[J]. JAMA, 2025, 333(18): 1608-1617.
|
| 27 |
Zalucky AA, Dianti J, Neyton LPA, et al. Elastance may determine the neuromuscular blockade effect on mortality in acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2025, 211(6): 966-974.
|
| 28 |
Brunini M, Forel JM, Muracciole X, et al. Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial[J]. Intensive Care Med, 2025, 51(9): 1615-1627.
|
| 29 |
Goligher EC, Costa ELV, Yarnell CJ, et al. Effect of lowering Vt on mortality in acute respiratory distress syndrome varies with respiratory system elastance[J]. Am J Respir Crit Care Med, 2021, 203(11): 1378-1385.
|
| 30 |
Lakbar I, De Jong A, Battaglini D. Refining the use of neuromuscular blockade in ARDS: lessons from a post hoc Markov model re-analysis of the ACURASYS trial[J]. Intensive Care Med, 2025, 51(12): 2399-2402.
|
| 31 |
de Grooth HJ, Yehya N, Harhay MO. Credible subgroup effects in randomized clinical trials[J]. Am J Respir Crit Care Med, 2025, 211(6): 893-895.
|
| 32 |
Laffey JG, Matthay MA. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value[J]. Am J Respir Crit Care Med, 2017, 196(3): 266-273.
|
| 33 |
Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial[J]. Lancet Respir Med, 2019, 7(2): 154-162.
|
| 34 |
Matthay MA, Zhuo H, Sarma A, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome: a double-blind, placebo-controlled, multicenter phase 2b clinical trial (STAT)[J]. Am J Respir Crit Care Med, 2026, 212(3): 428-439.
|
| 35 |
Wu Y, Xu R, Li Y, et al. Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis[J]. Stem Cell Res Ther, 2025, 16(1): 522.
|